The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Improving the outcomes of patients with MCL who progress on BTK inhibitors
In this video, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, provides insight into the potential approaches for improving outcomes in patients with mantle cell lymphoma (MCL) who progress on BTK inhibitor (BTKi) therapy. Dr Kamdar highlights the benefits of bringing BTKis into frontline treatment and the potential of agents such as pirotbrutinib and sonrotoclax for treating patients who ultimately progress on covalent BTKis. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
